Grünenthal GmbH has appointed Janneke van der Kamp as chief commercial officer, effective 1 March 2023 to help prepare for the market launch of new medicines. The company’s therapeutic focus is pain management and related diseases. Ms van der Kamp will join from Novartis where she most recently served as head of pharmaceuticals for Europe. She has also led Novartis’ global neuroscience business. Ms van der Kamp will succeed Mark Fladrich who will retire on 28 February 2023.
Ms van der Kamp holds a master’s degree in chemistry from Utrecht University in the Netherlands and a master of business administration degree from INSEAD in France.
She also has a bachelor’s degree in music.
Grünenthal announced the appointment on 22 November 2022.
Copyright 2022 Evernow Publishing Ltd